Selling, General, and Administrative Costs: Pfizer Inc. vs Alkermes plc

A Comparative Analysis of SG&A Expenses: Pfizer Inc. vs. Alkermes plc

In the ever-evolving pharmaceutical industry, understanding the financial dynamics of major players is crucial. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of Pfizer Inc. and Alkermes plc from 2014 to 2023. Over this period, Pfizer's SG&A expenses have consistently dwarfed those of Alkermes, averaging around $14 billion annually, compared to Alkermes' $482 million. Notably, Pfizer's expenses peaked in 2016, reaching approximately $14.8 billion, while Alkermes saw a steady increase, culminating in a 245% rise from 2014 to 2023. This disparity highlights the scale and operational differences between the two companies. As Pfizer navigates its vast global operations, Alkermes focuses on niche markets, reflected in their financial strategies. This data offers a window into the strategic priorities and market positioning of these pharmaceutical giants.